A Phase I/II Study of Adoptive T Cell Therapy Following in vivo Priming with a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients with Advanced Stage HER2 Overexpressing (HER2+) Breast Cancer Scientific Description |
Clinical Description
Phase I-II Study of HER2 Vaccination with poly(I) • poly(C-12-U)(Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients Scientific Description |
Clinical Description
